Literature DB >> 19061911

Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist.

Gery Schulteis1, David Chiang, Clay Archer.   

Abstract

The current study compared the potency of naloxone versus 6-alpha-naloxol to precipitate opioid withdrawal under varying conditions of morphine pretreatment history using suppression of operant responding for food reward as the index of withdrawal. Male Wistar rats trained to respond on a lever for food reward received pretreatment with either Vehicle (Morphine-Naïve), a single subcutaneous (SC) injection of 5.6 mg/kg morphine (Single Morphine), or two morphine injections at 24 h intervals (Repeat Morphine), with varying doses of naloxone or 6-alpha-naloxol injected SC 4 h post-morphine and 5 min prior to the 30 min test session. When responding over the entire 30 min operant session was examined, naloxone was only 5-fold more potent than 6-alpha-naloxol in suppressing operant responding under Morphine Naïve conditions, but this increased to a 65-fold potency difference after Single or Repeat Morphine pretreatment. Examination of the relative potency of these antagonists in the Early Phase of operant testing (5-15 min post-antagonist) revealed an even greater 100-fold potency difference between naloxone and 6-alpha-naloxol, but in the Late Phase of testing (25-35 min post-antagonist), this had declined to a 9-fold potency difference, comparable to the relative potency of naloxone to 6-alpha-naloxol under Morphine-Naïve conditions. The results confirm a differential potency of naloxone to its reduced conjugate 6-alpha-naloxol in vivo, and extend the observation of this phenomenon to an acute (single) pretreatment with a low dose of morphine and an additional sign of opioid withdrawal to those previously used. However, the results also indicate that delay in onset of action of 6-alpha-naloxol at opioid receptors in the central nervous system may contribute significantly to its reduced potency relative to naloxone under certain morphine pretreatment conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061911      PMCID: PMC2652854          DOI: 10.1016/j.pbb.2008.11.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  45 in total

1.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.

Authors:  D Wang; K M Raehal; E J Bilsky; W Sadée
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

3.  Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.

Authors:  J G Liu; P L Prather
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

4.  Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.

Authors:  D Wang; C K Surratt; W Sadée
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

5.  Acute opioid but not benzodiazepine dependence in rats responding for intracranial self-stimulation.

Authors:  K W Easterling; R M Plovnick; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

6.  Changes in urination/defecation, auditory startle response, and startle-induced ultrasonic vocalizations in rats undergoing morphine withdrawal: similarities and differences between acute and chronic dependence.

Authors:  Mikhail Kalinichev; Stephen G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

7.  Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal.

Authors:  Marc R Azar; Byron C Jones; Gery Schulteis
Journal:  Psychopharmacology (Berl)       Date:  2003-05-29       Impact factor: 4.530

8.  Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze.

Authors:  Zhongqi Zhang; Gery Schulteis
Journal:  Pharmacol Biochem Behav       Date:  2008-01-29       Impact factor: 3.533

9.  Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.

Authors:  Jing-Gen Liu; Paul L Prather
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  Repeated experience with naloxone facilitates acute morphine withdrawal: potential role for conditioning processes in acute opioid dependence.

Authors:  Gery Schulteis; Andrew C Morse; Jian Liu
Journal:  Pharmacol Biochem Behav       Date:  2003-12       Impact factor: 3.533

View more
  2 in total

1.  The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice.

Authors:  Dipesh M Navani; Sunil Sirohi; Priyanka A Madia; Byron C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2011-06-29       Impact factor: 3.533

Review 2.  The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Authors:  Nalini Vadivelu; Erika Schermer; Gopal Kodumudi; Jack M Berger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.